1. Home
  2. APLS
  3. APLS News

Latest Apellis Pharmaceuticals Inc. (APLS) News on October 26, 2025

APLS

MT Newswires

24 days ago

Apellis Pharmaceuticals Insider Sold Shares Worth $702,057, According to a Recent SEC Filing

Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?
APLS

Zacks

4 months ago

Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?

Sobi and Apellis report new data from Phase III trial for C3G and IC-MPGN
APLS

Clinical Trials Arena

5 months ago

Sobi and Apellis report new data from Phase III trial for C3G and IC-MPGN

Apellis, Sobi present data from open-label period of Phase 3 VALIANT study
APLS

TipRanks

5 months ago

Apellis, Sobi present data from open-label period of Phase 3 VALIANT study

Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?
APLS

Zacks

5 months ago

Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?

APLS

MT Newswires

5 months ago

Apellis Pharmaceuticals, Sobi Report Empaveli's Sustained Efficacy at 1 Year in Phase 3 Study

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
APLS

GlobeNewswire

5 months ago

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

High Growth Tech Stocks To Watch In The US June 2025
APLS

Simply Wall St.

5 months ago

High Growth Tech Stocks To Watch In The US June 2025

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
APLS

GlobeNewswire

5 months ago

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday
APLS

Insider Monkey

5 months ago

Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday

APLS

MT Newswires

5 months ago

Mizuho Securities Adjusts Apellis Pharmaceuticals Price Target to $20 From $30, Maintains Neutral Rating

APLS

MT Newswires

6 months ago

Apellis Pharmaceuticals' Funding Gaps, Weak Syfovre Sales Cloud Outlook, BofA Says

Apellis price target lowered to $20 from $28 at Scotiabank
APLS

TipRanks

6 months ago

Apellis price target lowered to $20 from $28 at Scotiabank

APLS

Investing.com

6 months ago

Apellis Pharmaceuticals downgraded by Raymond James due to ’added uncertainty’

Is Apellis Pharmaceuticals, Inc. (APLS) The Best Stock That Will Bounce Back?
APLS

Insider Monkey

6 months ago

Is Apellis Pharmaceuticals, Inc. (APLS) The Best Stock That Will Bounce Back?

APLS

MT Newswires

6 months ago

Raymond James Downgrades Apellis Pharmaceuticals to Outperform From Strong Buy, Adjusts Price Target to $52 From $75

APLS

MT Newswires

6 months ago

BofA Securities Downgrades Apellis Pharmaceuticals to Neutral, Price Target is $23

Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
APLS

Zacks

6 months ago

Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down

APLS

MT Newswires

6 months ago

RBC Cuts Price Target on Apellis Pharmaceuticals to $18 From $21, Keeps Sector Perform Rating

Apellis Pharmaceuticals Inc (APLS) Q1 2025 Earnings Call Highlights: Strong Market Leadership ...
APLS

GuruFocus.com

6 months ago

Apellis Pharmaceuticals Inc (APLS) Q1 2025 Earnings Call Highlights: Strong Market Leadership ...

APLS

Thomson Reuters StreetEvents

6 months ago

Q1 2025 Apellis Pharmaceuticals Inc Earnings Call

Why Apellis Pharmaceuticals Wilted on Wednesday
APLS

Motley Fool

6 months ago

Why Apellis Pharmaceuticals Wilted on Wednesday

Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say
APLS

Zacks

6 months ago

Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say

APLS

MT Newswires

6 months ago

Apellis Pharmaceuticals Q1 Loss Widens, Revenue Decreases

Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates
APLS

Zacks

6 months ago

Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
APLS

GlobeNewswire

6 months ago

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
APLS

GlobeNewswire

6 months ago

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

High Growth Tech Stocks In The US For May 2025
APLS

Simply Wall St.

6 months ago

High Growth Tech Stocks In The US For May 2025

Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know
APLS

Zacks

6 months ago

Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
APLS

GlobeNewswire

6 months ago

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

Is Apellis Pharmaceuticals, Inc. (APLS) the Best Oversold NASDAQ Stock to Buy Right Now?
APLS

Insider Monkey

6 months ago

Is Apellis Pharmaceuticals, Inc. (APLS) the Best Oversold NASDAQ Stock to Buy Right Now?

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
APLS

Zacks

6 months ago

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
APLS

Insider Monkey

6 months ago

Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

APLS

MT Newswires

6 months ago

RBC Cuts Price Target on Apellis Pharmaceuticals to $21 From $24, Keeps Sector Perform Rating

Apellis Announces Craig Wheeler to Join the Board of Directors
APLS

GlobeNewswire

6 months ago

Apellis Announces Craig Wheeler to Join the Board of Directors

APLS

MT Newswires

6 months ago

BofA Adjusts Price Target on Apellis Pharmaceuticals to $41 From $44, Keeps Buy Rating

BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?
APLS

Zacks

6 months ago

BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?

APLS

MT Newswires

7 months ago

RBC Trims Price Target on Apellis Pharmaceuticals to $24 From $25, Keeps Sector Perform Rating

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag
APLS

Zacks

7 months ago

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseases
APLS

Pharmaceutical Technology

7 months ago

FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseases

APLS

MT Newswires

7 months ago

Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
APLS

GlobeNewswire

7 months ago

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Exploring US High Growth Tech Stocks In March 2025
APLS

Simply Wall St.

7 months ago

Exploring US High Growth Tech Stocks In March 2025

Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts
APLS

Insider Monkey

7 months ago

Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts

Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli
APLS

TipRanks

7 months ago

Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
APLS

Benzinga

8 months ago

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

APLS

MT Newswires

8 months ago

UBS Adjusts Apellis Pharmaceuticals Price Target to $43 From $45, Maintains Buy Rating

Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues
APLS

Zacks

8 months ago

Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues

APLS

MT Newswires

8 months ago

Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $29 From $30, Keeps Neutral Rating

APLS

MT Newswires

8 months ago

RBC Trims Price Target on Apellis Pharmaceuticals to $25 From $26, Keeps Sector Perform Rating

Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
APLS

Simply Wall St.

8 months ago

Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...
APLS

GuruFocus.com

8 months ago

Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...

APLS

Thomson Reuters StreetEvents

8 months ago

Q4 2024 Apellis Pharmaceuticals Inc Earnings Call

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics
APLS

Zacks

8 months ago

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics

APLS

MT Newswires

8 months ago

Sector Update: Health Care Stocks Steady Pre-Bell Friday

Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates
APLS

Zacks

8 months ago

Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates

APLS

MT Newswires

8 months ago

Apellis Pharmaceuticals Q4 Net Loss Narrows, Revenue Rises

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
APLS

GlobeNewswire

8 months ago

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

What To Expect From Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings
APLS

GuruFocus.com

8 months ago

What To Expect From Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
APLS

Zacks

8 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
APLS

GlobeNewswire

8 months ago

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Why Apellis Pharmaceuticals, Inc. (APLS) is the Most Oversold Pharma Stock to Buy According to Analysts
APLS

Insider Monkey

8 months ago

Why Apellis Pharmaceuticals, Inc. (APLS) is the Most Oversold Pharma Stock to Buy According to Analysts

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
APLS

Zacks

8 months ago

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

High Growth Tech Stocks In The United States To Watch
APLS

Simply Wall St.

8 months ago

High Growth Tech Stocks In The United States To Watch

Is Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now?
APLS

Insider Monkey

8 months ago

Is Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now?

APLS

MT Newswires

8 months ago

Apellis Pharmaceuticals, Sobi Say EMA Validated Indication Extension Application for Potential Kidney Disease Treatment

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
APLS

GlobeNewswire

8 months ago

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

Apellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In January
APLS

Insider Monkey

8 months ago

Apellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In January

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
APLS

GlobeNewswire

8 months ago

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Apellis Pharmaceuticals (NASDAQ:APLS investor one-year losses grow to 58% as the stock sheds US$231m this past week
APLS

Simply Wall St.

8 months ago

Apellis Pharmaceuticals (NASDAQ:APLS investor one-year losses grow to 58% as the stock sheds US$231m this past week

Why Insiders Are Selling Apellis Pharmaceuticals, Inc. (APLS) Recently
APLS

Insider Monkey

8 months ago

Why Insiders Are Selling Apellis Pharmaceuticals, Inc. (APLS) Recently

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
APLS

GlobeNewswire

9 months ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

APLS

MT Newswires

9 months ago

Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday

APLS

MT Newswires

9 months ago

Sector Update: Health Care

APLS

MT Newswires

9 months ago

Apellis Pharmaceuticals' Geographic Atrophy Treatment Gets Approval From Australian Therapeutic Goods Administration

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
APLS

GlobeNewswire

9 months ago

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

APLS

MT Newswires

9 months ago

Apellis Pharmaceuticals Insider Sold Shares Worth $412,296, According to a Recent SEC Filing

APLS

MT Newswires

9 months ago

Wedbush Raises Price Target on Apellis Pharmaceuticals to $30 From $25, Keeps Neutral Rating

APLS

MT Newswires

9 months ago

Apellis Shares Rise After Reporting Preliminary Q4, Full-Year Product Sales Results

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
APLS

GlobeNewswire

9 months ago

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

Apellis Announces Keli Walbert to Join the Board of Directors
APLS

GlobeNewswire

10 months ago

Apellis Announces Keli Walbert to Join the Board of Directors

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
APLS

GlobeNewswire

10 months ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

APLS

MT Newswires

10 months ago

RBC Raises Price Target on Apellis Pharmaceuticals to $26 From $24, Keeps Sector Perform Rating

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
APLS

GlobeNewswire

10 months ago

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Exploring 3 High Growth Tech Stocks In The United States
APLS

Simply Wall St.

10 months ago

Exploring 3 High Growth Tech Stocks In The United States

APLS

MT Newswires

10 months ago

Goldman Sachs Downgrades Apellis Pharmaceuticals to Neutral From Buy, $36 Price Target

Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?
APLS

Zacks

10 months ago

Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?

Should You Hold Apellis Pharmaceuticals (APLS)?
APLS

Insider Monkey

10 months ago

Should You Hold Apellis Pharmaceuticals (APLS)?

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
APLS

GlobeNewswire

a year ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?
APLS

Zacks

a year ago

Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?

Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report?
APLS

Zacks

a year ago

Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report?

Exploring Three High Growth Tech Stocks in the United States
APLS

Simply Wall St.

a year ago

Exploring Three High Growth Tech Stocks in the United States

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
APLS

GlobeNewswire

a year ago

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
APLS

GlobeNewswire

a year ago

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

Apellis price target lowered to $30 from $43 at Wells Fargo
APLS

TipRanks

a year ago

Apellis price target lowered to $30 from $43 at Wells Fargo

Apellis price target lowered to $47 from $61 at BofA
APLS

TipRanks

a year ago

Apellis price target lowered to $47 from $61 at BofA

Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
APLS

Zacks

a year ago

Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

APLS

MT Newswires

a year ago

RBC Capital Trims Price Target on Apellis Pharmaceuticals to $24 From $25, Maintains Sector Perform Rating

APLS

MT Newswires

a year ago

Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $40 From $65, Maintains Outperform Rating

Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlights: Revenue Surge and ...
APLS

GuruFocus.com

a year ago

Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlights: Revenue Surge and ...

Share on Social Networks: